About: COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
Creator	Faisal, Shah Jan, Hasnain Khan, Ayyaz Khan, Shahzar Liaqat, Rabia Shah, Sajjad Usman, Hazrat
source	Medline; PMC; WHO
abstract	An epidemic of extreme respiratory deterrence, pneumonia and shortness of breath, the SARS-CoV-2 viral infection began in Wuhan, Hubei Province, China in December 2019, and rapidly spread across China and beyond, with human to human transmission. On February 12, 2020, World Health Organization officially named the new coronavirus disease as coronavirus disease 19 (COVID-19). Most COVID-19 patients were diagnosed with pneumonia and many were treated using Chinese medicines and other secondary therapies. As of April 22, 2020, the total figure of infected patients has crossed 2.6 million people worldwide with over 180,000 deaths and 700,000 patients that have recovered. Preliminary reports suggest that certain drugs, such as chloroquine and antiviral nucleotide analogues such as remdesivir, which inhibit viral replication, can target the new coronavirus, although their usefulness in the clinic is still under debate. An expert US committee developed the US NIH guidelines for COVID-19 treatment, which was just released and will be regularly updated. This manuscript reviews the epidemiology, etiology, mortality, COVID-19 clinical symptoms, and potential therapeutic drugs, while highlighting the seriousness and damage-induced by SARS-CoV-2.
has issue date	2020-04-26(xsd:dateTime)
bibo:doi	10.15190/d.2020.5
bibo:pmid	32377559
has license	cc-by
sha1sum (hex)	c540b5c7f8fda5460d0581c2b4fbf5dfd97a3141
schema:url	https://doi.org/10.15190/d.2020.5
resource representing a document's title	COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus
has PubMed Central identifier	PMC7199242
has PubMed identifier	32377559
schema:publication	Discoveries
resource representing a document's body	covid:c540b5c7f8fda5460d0581c2b4fbf5dfd97a3141#body_text
is schema:about of	named entity '2019 Novel Coronavirus' named entity 'humanized monoclonal antibody' named entity 'SARS-CoV' named entity 'clinical trials' named entity 'CCR5' named entity 'WHO' named entity 'ritonavir' named entity 'HIV protease inhibitors' named entity 'Biotechnology' named entity 'single-stranded RNA' named entity 'membrane protein' named entity 'COVID-19' named entity 'HCoV-OC43' named entity 'COVID' named entity 'nucleoside' named entity 'morbidity' named entity 'remdesivir' named entity 'Baricitinib' named entity 'human infection' named entity 'polyprotein' named entity 'lymphopenia' named entity '11.1' named entity 'coronaviruses' named entity 'Huh-7' named entity 'glycosylation' named entity 'Guangdong Province' named entity 'hydroxychloroquine' named entity 'JAMA' named entity 'chloroquine' named entity 'Off-label' named entity 'virus' named entity 'Hubei Province' named entity 'RNA viruses' named entity 'China' named entity 'virus infections' named entity 'cell membranes' named entity 'genome' named entity 'Chinese herbal' named entity 'incubation period' named entity 'protein kinase' named entity 'high-risk' named entity 'Hydroxychloroquine' named entity 'plasma' named entity 'Department of Science and Technology' named entity 'chloroquine' named entity 'oral administration' named entity 'polymerase' named entity 'lymphopenia' named entity 'virus' named entity 'SARS-CoV' named entity 'oseltamivir' named entity 'virus' named entity 'COVID-19' named entity 'experimental group' named entity 'province of China' named entity 'infectious disease' named entity 'Animal experiments' named entity 'mortality rate' named entity 'remdesivir' named entity 'surface spikes' named entity 'WHO' named entity 'MERS-CoV' named entity 'mesenchymal stem cell' named entity 'malaria' named entity 'chloroquine' named entity 'cell receptors' named entity 'bradycardia' named entity 'remdesivir' named entity 'ondansetron' named entity 'antiviral medication' named entity '11.1' named entity 'respiratory failure' named entity 'lung' named entity 'flu-like symptoms' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software